Three subtypes of IPS values (IPS-CTLA4 positive, IPS-PD-1/PD-L1/PD-L2 positive, and IPS-CTLA4/PD-1/PD-L1/PD-L2 positive) were served to evaluate responses of glioma patients to immunotherapy. This evidence concerns the gene PDCD1LG2 and central nervous system cancer.